Locus Biosciences develops CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease.
Locus Biosciences has raised $35.0M in total funding. The most recent round was Series B. The last funding was announced in May 2022.
Locus Biosciences's investors include Abstract, Tencent, Starlight Ventures, Hercules Capital, Viking Global Investors.
Locus Biosciences is headquartered in Morrisville, United States.
Locus Biosciences develops CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease.
Locus Biosciences is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Locus Biosciences — Funding & Investors." VCBacked, May 18, 2022, https://www.vcbacked.co/company/locus-biosciences. Accessed September 9, 2026.
VCBacked. (2022). Locus Biosciences — Funding & Investors. Retrieved September 9, 2026, from https://www.vcbacked.co/company/locus-biosciences
{{cite web |title=Locus Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/locus-biosciences |website=VCBacked |access-date=September 9, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated